Neuroprotective Therapy for Neonatal Encephalopathy

Neonatal hypoxic-ischemic encephalopathy (HIE) is a brain dysfunction condition in newborns due to inadequate oxygen and blow flow to the brain at term or near birth. It affects 1-2 per 1,000 live births in high-resource countries ().

HIE is the reason for the deaths of over half a million worldwide each year. Therapeutic hypothermia is the standard treatment for moderate to severe HIE. Many infants treated with hypothermia still experience significant motor, cognitive and behavioral disabilities by school age.

‘New therapies are emerging to protect newborns from Hypoxic-Ischemic Encephalopathy (HIE), targeting brain injury mechanisms like inflammation & oxidative stress. #neuroprotection #HIE #newbornhealth #medindia’

In low-income regions therapeutic hypothermia is unavailable and the need for new, accessible treatment is urgent.

Therapies for Neuroprotection in Neonatal Hypoxic-Ischemic Encephalopathy

A recent review has highlighted cutting-edge approaches to protect the newborn brain. These therapies target complex mechanisms of HIE related brain injury including inflammation, oxidative stress and cell death.

• Anti-excitotoxic agents like magnesium sulfate and xenon can limit brain damage caused by excessive glutamate release.
• Antioxidants such as allopurinol and melatonin reduce oxidative stress and improve the condition when combined with other therapies.
• Multi-mechanism agents like cannabidiol and caffeine promote neuroregeneration while addressing multiple pathways of injury.
• Stem cell therapy can repair brain damage through regenerative mechanisms.

Challenges in Implementing Alternative Therapies

Preclinical studies show promising results but implementing these therapies into effective clinical treatments for neonatal HIE presents many difficulties:

• Identifying the ideal time for administering neuroprotective therapies with the timing of hypoxic-ischemic events is important.
• The timing, severity and location of brain injury in hypoxic-ischemic encephalopathy can vary significantly between individuals.
• Need for reliable biomarkers that can assess the severity and progression of brain injury in real time, which can lead to more personalized and accurate treatment.
• Safe and effective delivery of these therapies to infants poses a significant challenge.

Advancements in personalized medicine and combined therapies can improve treating newborns with HIE. The development of affordable and accessible treatments can revolutionize care for this life-altering condition and give hope to families.

Reference:

1. Neuroprotection for neonatal hypoxic-ischemic encephalopathy: a review of novel therapies evaluated in clinical studies- (https:onlinelibrary.wiley.com/doi/10.1111/dmcn.16184)

Source: Medindia